Symbolic image GLP-1 Peptides Reshape Grocery: Less Snacks, More Protein
GLP-1 peptide drugs like semaglutide and tirzepatide are changing not just appetites but entire grocery baskets.
In context
Peptide news
Research, regulation, safety and market around peptides - briefly contextualized and sourced.
48 posts ·continuously updated ·independent & ad-free
Symbolic image 
When my vial ran empty too soon
My tirzepatide vial was empty sooner than calculated. The cause was a tiny mistake when mixing - and without a clean log, I'd never have noticed.
Symbolic image FDA Warning Letters: 7 Peptide Shops Named for Retatrutide
On April 7, 2026, the FDA published seven warning letters to peptide shops including Gram Peptides, Mile High Compounds, and Prime Sciences for selling unapproved retatrutide, tirzepatide, and cagrilintide as research chemicals.
Symbolic image Whey Protein Crisis: Prices Fivefold Since 2023
The whey protein crisis has escalated dramatically: prices have increased fivefold since 2023, with WPC80 exceeding $14 per pound. The GLP-1 boom and increased protein requirements are driving demand - while production capacity
Symbolic image Fake Retatrutide: Six Acute Liver Injuries in Australia
Since January 2026, six people in Victoria, Australia have suffered acute liver injury after using unapproved peptide products labelled as Retatrutide. Authorities consider contamination the most likely cause.
Symbolic image Tirzepatide for Sleep Apnea: SURMOUNT-OSA & FDA Approval
Tirzepatide (Zepbound) is the first drug approved by the FDA for obstructive sleep apnea (OSA) in adults with obesity. The SURMOUNT-OSA trial shows up to 63% reduction in apnea-hypopnea index.
Symbolic image FDA Rules Out Suicide Risk for GLP-1 Weight-Loss Drugs
On January 13, 2026, the FDA officially confirmed that GLP-1 drugs like semaglutide and tirzepatide do not increase suicide risk. The suicide warning is being removed from drug labels.
Symbolic image Scam Alert: New Fraud Vendors + FDA Warns of Counterfeit
Three new scam vendors have been verified on the Vendor Radar, while the FDA warns of counterfeit Ozempic (semaglutide) in the supply chain and launches Import Alert 66-80 against illegal GLP-1 imports.
Symbolic image FDA: 25 Warning Letters to Telehealth GLP-1 Compounders
The FDA sent a third wave of 25 warning letters to telehealth companies in mid-June 2026 for misleading claims about compounded GLP-1 drugs. The agency warns patients about unapproved copycat products.